ZIVO Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZIVO research report →
Range $12 – $12
Price Chart
About the company
ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods.
- CEO
- John Bernard Payne
- IPO
- 2003
- Employees
- 7
- HQ
- Troy, MI, US
Get TickerSpark's AI analysis on ZIVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.49M
- P/E
- -3.03
- PEG
- -0.05
- P/S
- 251.24
- P/B
- -5.20
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
- Gross Margin
- 32.44%
- Op Margin
- -8327.18%
- Net Margin
- -8388.36%
- ROE
- 159.08%
- ROIC
- 194.30%
Latest fiscal year · YoY change
- Revenue
- $119.03K-24.3%
- Gross Profit
- $39.93K-18.4%
- Op Income
- $-9,853,893
- Net Income
- $-9,892,305+26.1%
- EPS
- $-2.59+33.9%
- OCF Growth
- +23.8%
- FCF Growth
- +23.8%
- 52W High
- $17.50
- 52W Low
- $1.11
- 50D MA
- $3.86
- 200D MA
- $5.62
- Beta
- 0.11
- RSI (14)
- 63
- Avg Volume
- 543
No earnings-call transcripts are available for ZIVO yet.
- Free Float
- 37.9%
- Shares Outstanding
- 3.89M
- Float Shares
- 1.47M
of shares held by institutions
11 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | STROME MARK E | buy | 100,000 |
| Feb 27, 26 | YALDOO LAITH L | buy | 1,543 |
| Feb 12, 26 | STROME MARK E | buy | 20,000 |
| Feb 12, 26 | STROME MARK E | buy | 2,000 |
| Feb 10, 26 | YALDOO LAITH L | buy | 2,434 |
| Jan 26, 26 | Cornell Alison A | buy | 11,709 |
| Jan 26, 26 | PAYNE JOHN BERNARD | buy | 11,709 |
| Jan 14, 26 | Maggiore Christopher D. | buy | 1,766 |
| Jan 14, 26 | YALDOO LAITH L | buy | 1,766 |
| Dec 19, 25 | Sullivan William A. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZIVO coverage
Recent articles, reports, and earnings notes.
No research on ZIVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZIVO report →Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
businesswire.com · May 12
ZIVO Bioscience Provides Special Letter to Shareholders
businesswire.com · Mar 27
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
defenseworld.net · Jan 6
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
businesswire.com · Sep 10
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
businesswire.com · Jun 20
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
businesswire.com · May 6
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
businesswire.com · Feb 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.